Breaking News Instant updates and real-time market news.

INGN

Inogen

$78.98

0.28 (0.36%)

, TFX

Teleflex

$274.59

-2.3 (-0.83%)

05:18
04/23/19
04/23
05:18
04/23/19
05:18

Piper sees Q1 revenue upside for Inogen, Teleflex, Align Technology

Piper Jaffray analyst Matt O'Brien says his deep dive into the MedTech companies exploring the direct-to-consumer sales channel came up "most compelling" for Inogen (INGN), Teleflex (TFX) and Align Technology (ALGN). Website traffic at these companies is at or near three-year highs and historical trends suggest a high likelihood of revenue upside in Q1, O'Brien tells investors in a research note. The analyst also found DexCom's (DXCM) website traffic to be at three-year highs.

INGN

Inogen

$78.98

0.28 (0.36%)

TFX

Teleflex

$274.59

-2.3 (-0.83%)

ALGN

Align Technology

$290.78

9.28 (3.30%)

DXCM

DexCom

$116.63

2.21 (1.93%)

  • 24

    Apr

  • 24

    Apr

  • 01

    May

  • 02

    May

  • 03

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 15

    May

  • 05

    Jun

  • 12

    Jun

  • 13

    Nov

INGN Inogen
$78.98

0.28 (0.36%)

04/03/19
PIPR
04/03/19
NO CHANGE
Target $185
PIPR
Overweight
Inogen price increase an unexpected positive, says Piper Jaffray
Piper Jaffray analyst JP McKim notes that the Inogen G5 officially was released to customers via the DTC channel and will be made available BTB domestic and BTB international in the coming months through a controlled roll out. The analyst says that the company can now market the G5 as market leading on all important categories like weight, flow rate, battery life and sound and will therefore go for a premium price. The company is increasing its minimum advertised price to $2,995 for the G5, up from $2,300 for G4/G3, he points out, adding that he believes this price increase was not expected by investors and sees it as a positive as people adjust their models. McKim reiterates an Overweight rating and $185 price target on the shares.
04/21/19
PIPR
04/21/19
NO CHANGE
Target $185
PIPR
Overweight
Oxygen survey confirms TAM, supports Inogen bull thesis, says Piper Jaffray
Piper Jaffray analyst JP McKim believes his oxygen survey debunks a lot of the bearish arguments around the Medicare Claims data and supports his long-term Inogen bull thesis. That said, the survey did not give him a ton of confidence in near-term BTB results. While the analyst does not get the sense Q1 is going to be the snap back quarter like he expects Q2 to be, he argues that with the stock at $79, a lot of that is already reflected in the share price. Finally, as investors have been solely relying on the Medicare claims data for market sizing, McKim believes this survey provides another data point to confirm the market is large, still growing, and shifting to POCs. He reiterates an Overweight rating and $185 price target on the shares.
03/11/19
PIPR
03/11/19
NO CHANGE
Target $185
PIPR
Overweight
Inogen recent share selloff 'way overdone,' says Piper Jaffray
After visiting the company's headquarters and meeting with its CFO, Piper Jaffray analyst JP McKim says the recent pullback in shares of Inogen is "way overdone." While the analyst does not expect "anything heroic in terms of a massive bounce back" in Q1 business-to-business sales, he points out that management did seem more open to a stock buyback program than they have in previous meetings. In 10 years, there will not be patients wheeling around oxygen tanks and Inogen remains the best way to play this "thematic shift," McKim tells investors in a research note. He keeps an Overweight rating on the shares with a $185 price target. The stock closed Friday down $3.28 to $93.95.
03/08/19
PIPR
03/08/19
NO CHANGE
PIPR
Overweight
Piper says CMS 2021 competitive bidding outline in-line with expectations
Piper Jaffray analyst JP McKim noted that CMS announced its plans for Round 2021 of competitive bidding yesterday, telling investors that a lot of the updates were in line with the firm's November call with key opinion leaders. The biggest changes are lead item pricing, which separated CPAP and Oxygen, a change from mean bid price to maximum bid price, required surety bonds of $50,000 and updated policy to licensure/accreditation requirements. The sum of both the Portable Oxygen Concentrator codes and tank codes, which is normally how a rental gets billed, is likely to be plus or minus 10%, projected McKim. If that proves true, he sees "nothing that would stop the shift to POCs away from tanks," which he said is good for Inogen. McKim keeps an Overweight rating on Inogen shares.
TFX Teleflex
$274.59

-2.3 (-0.83%)

11/01/18
PIPR
11/01/18
NO CHANGE
Target $310
PIPR
Overweight
Teleflex price target raised to $310 from $295 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target on Teleflex to $310 and kept his Overweight rating while also increasing his FY18 EPS view to $9.90 from $9.83 after its Q3 earnings beat. The analyst notes that the company's organic growth of 5.6% was much stronger than expected, as the management also affirmed its 2018 organic growth forecast of 5.0%-5.5%. O'Brien expects Teleflex business to continue to deliver this year while its product flow for Percuvance & RePlas lifts the FY19 numbers, improving investor sentiment "markedly".
11/27/18
UBSW
11/27/18
INITIATION
UBSW
Buy
Teleflex initiated with a Buy at UBS
UBS analyst Matthew Taylor initiated Teleflex with a Buy rating and $310 price target, calling the stock a Top Buy for Growth/Momentum. Taylor said "We think investors should buy Teleflex ahead of improving revenue performance in 2019+ given acceleration from acquired products and the pipeline."
02/21/19
SPHN
02/21/19
NO CHANGE
SPHN
Stephens reiterates Overweight rating on Teleflex following Q4 results
Stephens analyst Chris Cooley reiterated an Overweight rating and $300 price target on Teleflex following the company's Q4 earnings report. The analyst noted that Teleflex's Q4 results were "modestly above consensus" and CY19 operating guidance "bracketed pre-call consensus expectations for revenue and earnings growth." Cooley sees the potential for upside through the year "stemming from faster organic growth, potential contributions from new products and ongoing operating cost savings."
03/22/19
UBSW
03/22/19
NO CHANGE
Target $350
UBSW
Buy
Teleflex price target raised to $350 from $325 at UBS
UBS analyst Matthew Taylor raised his price target on Teleflex to $350 and kept his Buy rating, saying its investor meeting discussions suggested that the management is confident in 2019 growth outlook of 6%-7%. The analyst cites the strength of the company's portfolio, acquisitions like NeoTract,Vascular Solutions, and Vidacare, as well as the impact of its eliminated "drags" associated with slower growth and margin business assets. Taylor believes that while the consensus models a 6.5% revenue growth this year, upside to that forecast is "very doable".
ALGN Align Technology
$290.78

9.28 (3.30%)

03/28/19
PIPR
03/28/19
NO CHANGE
Target $300
PIPR
Overweight
Align Technology patent settlement a positive, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and $300 price target on Align Technology after its announced settlement agreement with Straumann Group on a patent dispute going on for multiple years. The analyst sees the development as a positive for Align Technology as it removes the litigation expense and also allows the company to "tap into Straumann's significant distribution in Europe."
03/25/19
FBCO
03/25/19
NO CHANGE
Target $278
FBCO
Outperform
Align Technology price target raised to $278 from $270 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for Align Technology to $278 from $270 after hosting an investor meeting with the company's CEO Joe Hogan and CFO John Morici. The analyst cited greater conviction in near- and longer-term growth prospects. She reiterates an Outperform rating on the shares.
04/17/19
GUGG
04/17/19
INITIATION
Target $335
GUGG
Buy
Align Technology initiated with a Buy at Guggenheim
Guggenheim initiated Align Technology with a Buy and $335 price target.
04/17/19
GUGG
04/17/19
INITIATION
Target $335
GUGG
Buy
Align Technology initiated with a Buy at Guggenheim
Guggenheim analyst Glen Santangelo initiated Align Technology with a Buy rating and a price target of $335. The analyst says the stock price has started to recover recently following a 53% peak to trough pullback in Q4, as investors appear to have "digested the concerns around decelerating growth and pricing." With "no meaningful competition on the horizon", Santangelo is retaining his positive view on the "global penetration opportunity" for Align Technology, given the low global penetration for its clear aligners and iTero scanners as well as signs of traction in the company's international market sales efforts.
DXCM DexCom
$116.63

2.21 (1.93%)

04/09/19
SPHN
04/09/19
NO CHANGE
Target $170
SPHN
Overweight
Medtronic outcomes-based program could be headwind for DexCom, says Stephens
After Medtronic (MDT) announced that the company has reached a deal with Blue Cross and Blue Shield of Minnesota on an outcomes-based program for the company's Guardian Connect Continuous Glucose Monitoring system, Stephens analyst Chris Cooley said the program could potentially represent an incremental headwind to Dexcom's (DXCM) revenue growth if applied across a larger setting. However, Cooley is maintaining his calendar 2019 and 2020 estimates for Dexcom and keeps an Overweight rating on shares with a $170 price target.
02/22/19
COWN
02/22/19
NO CHANGE
Target $175
COWN
Outperform
DexCom price target raised to $175 from $150 at Cowen
Cowen analyst Doug Schenkel raised his price target on DexCom to $175 from $150 following its "blowout" Q4 results. The analyst believes its guidance leaves plenty of room for top and bottom line upside, though he admits a new competitor product could provide headline risk. He views the shares as a long-term core holding. Schenkel reiterated his Outperform rating on DexCom shares.
04/03/19
JPMS
04/03/19
NO CHANGE
Target $175
JPMS
Overweight
JPMorgan remains 'very bullish' on DexCom despite Libre 2.0 uncertainty
The latest DexCom (DXCM) controversy is "whirling speculation" around Abbott's (ABT) Libre 2.0 launch, JPMorgan analyst Robbie Marcus tells investors in a research note. The analyst keeps an Overweight rating on DexCom shares with a $175 price target but expects uncertainty over Libre 2.0 to remain an overhang until it receives U.S. approval. However, he remains "very bullish" on the shares and sees "significant upside" to 2019 estimates. DexComis the best positioned in diabetes longer-term, Marcus contends.
03/26/19
PIPR
03/26/19
NO CHANGE
Target $165
PIPR
Overweight
Piper discusses 16% selloff in DexCom over past three trading days
Piper Jaffray analyst JP McKim says he's fielded a lot of investor questions with shares of DexCom (DXCM) down 16% over the last three trading days. The crux of the selloff is Abbott's (ABT) Libre 2.0 and whether it gets interoperable continuous glucose monitoring and if so, what that does to volumes and price, McKim tells investors in a research note. The analyst sees little risk to DexCom's volumes for given the market inflection for continuous glucose monitoring, but adds that if Libre gets iCGM "payers maybe push a little harder on price." McKim admits that "headline risk is building around the approval" but keeps an Overweight rating on DexCom shares with a $165 price target. Libre 2.0 getting iCGM is not fully priced in the stock at this point, but some of that risk certainly is, says McKim.

TODAY'S FREE FLY STORIES

02:45
08/20/19
08/20
02:45
08/20/19
02:45
General news
FX Update: The Australian dollar has traded firmer »

FX Update: The Australian…

02:05
08/20/19
08/20
02:05
08/20/19
02:05
General news
Asian Market Wrap: »

Asian Market Wrap:…

NOVA

Sunnova Energy

$11.13

0.089 (0.81%)

21:22
08/19/19
08/19
21:22
08/19/19
21:22
Initiation
Sunnova Energy initiated at KeyBanc »

Sunnova Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SPY

SPDR S&P 500 ETF Trust

$292.31

3.52 (1.22%)

, SPX

S&P 500

$0.00

(0.00%)

20:54
08/19/19
08/19
20:54
08/19/19
20:54
Periodicals
Trump administration considering steps on economy if conditions worsen, NYT says »

White House officials…

SPY

SPDR S&P 500 ETF Trust

$292.31

3.52 (1.22%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$48.20

2.69 (5.91%)

, TJX

TJX

$51.55

0.13 (0.25%)

20:25
08/19/19
08/19
20:25
08/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KSS

Kohl's

$48.20

2.69 (5.91%)

TJX

TJX

$51.55

0.13 (0.25%)

MDT

Medtronic

$104.15

1.42 (1.38%)

HD

Home Depot

$207.98

4.335 (2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 04

    Sep

  • 09

    Sep

BHP

BHP Group

$49.12

0.31 (0.64%)

19:32
08/19/19
08/19
19:32
08/19/19
19:32
Hot Stocks
BHP Group sees China and global economic growth slowing »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BHP

BHP Group

$49.12

0.31 (0.64%)

19:25
08/19/19
08/19
19:25
08/19/19
19:25
Earnings
BHP Group reports FY19 Net profit up 124% at $8.31B »

Reports FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

AAPL

Apple

$210.32

3.88 (1.88%)

19:09
08/19/19
08/19
19:09
08/19/19
19:09
Periodicals
Apple aims for November launch of Apple+, Bloomberg reports »

Apple is targeting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$195.19

2.005 (1.04%)

19:04
08/19/19
08/19
19:04
08/19/19
19:04
Hot Stocks
Accenture acquires Parker Fitzgerald, terms not disclosed »

Accenture has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

BIDU

Baidu

$104.28

7.63 (7.89%)

, NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

18:47
08/19/19
08/19
18:47
08/19/19
18:47
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Baidu…

BIDU

Baidu

$104.28

7.63 (7.89%)

NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

MRNA

Moderna

$13.41

0.235 (1.78%)

VSLR

Vivint Solar

$8.30

0.3 (3.75%)

FN

Fabrinet

$56.40

0.77 (1.38%)

IQ

iQIYI

$18.10

1.02 (5.97%)

MRUS

Merus

$18.46

1.75 (10.47%)

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 04

    Sep

  • 09

    Sep

  • 12

    Sep

ET

Energy Transfer LP

$13.77

0.3 (2.23%)

18:40
08/19/19
08/19
18:40
08/19/19
18:40
Periodicals
Energy Transfer LP performing maintenance on WTG pipeline, Reuters says »

A spokeswoman for Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$210.32

3.88 (1.88%)

, SNE

Sony

$55.71

-0.01 (-0.02%)

18:20
08/19/19
08/19
18:20
08/19/19
18:20
Periodicals
Apple allocates over $6B for original TV shows and movies, FT says »

Apple (AAPL) has budgeted…

AAPL

Apple

$210.32

3.88 (1.88%)

SNE

Sony

$55.71

-0.01 (-0.02%)

NFLX

Netflix

$309.40

6.66 (2.20%)

DIS

Disney

$135.33

0.14 (0.10%)

T

AT&T

$35.40

0.42 (1.20%)

CBS

CBS

$44.21

0.38 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

LGIH

LGI Homes

$78.56

3.36 (4.47%)

18:01
08/19/19
08/19
18:01
08/19/19
18:01
Hot Stocks
LGI Homes opens two new communities in greater Seattle market »

LGI Homes announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

18:01
08/19/19
08/19
18:01
08/19/19
18:01
Hot Stocks
Amazon.com to expand in Utah with new new fulfillment center »

Amazon.com announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

WMT

Walmart

$113.76

0.77 (0.68%)

18:00
08/19/19
08/19
18:00
08/19/19
18:00
Hot Stocks
Walmart to pay $100,000 to settle EEOC disability discrimination suit »

Wal-Mart Stores East, LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

X

U.S. Steel

$12.42

1.13 (10.01%)

17:58
08/19/19
08/19
17:58
08/19/19
17:58
Periodicals
U.S. Steel to lay off hundreds of workers at Great Lakes plant, Reuters says »

U.S. Steel plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:53
08/19/19
08/19
17:53
08/19/19
17:53
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta falls over 4% or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:52
08/19/19
08/19
17:52
08/19/19
17:52
Hot Stocks
FDA's CRL to Sarepta's golodirsen citing risk of infection, renal toxicity »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BSX

Boston Scientific

$42.74

0.59 (1.40%)

17:41
08/19/19
08/19
17:41
08/19/19
17:41
Hot Stocks
Boston Scientific's ImageReady MRI labeling receives FDA approval »

Boston Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

, GOOG

Alphabet

$1,198.01

21.07 (1.79%)

17:35
08/19/19
08/19
17:35
08/19/19
17:35
Periodicals
State AGs to proceed with antitrust investigation of big tech, WSJ reports »

A group of state…

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

GOOG

Alphabet

$1,198.01

21.07 (1.79%)

GOOGL

Alphabet Class A

$1,199.94

21.25 (1.80%)

FB

Facebook

$186.22

2.8 (1.53%)

MSFT

Microsoft

$138.43

2.3 (1.69%)

AAPL

Apple

$210.32

3.88 (1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

FB

Facebook

$186.22

2.8 (1.53%)

17:31
08/19/19
08/19
17:31
08/19/19
17:31
Periodicals
FTC head says breaking up Facebook could be complicated, FT reports »

Federal Trade Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

MPW

Medical Properties Trust

$18.28

0.13 (0.72%)

17:28
08/19/19
08/19
17:28
08/19/19
17:28
Hot Stocks
Medical Properties Trust COO sells 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

WMT

Walmart

$113.76

0.77 (0.68%)

17:17
08/19/19
08/19
17:17
08/19/19
17:17
Periodicals
Walmart's U.S. Chief Marketing Officer Barbara Messing is leaving, AdAge says »

Walmart U.S. Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

MAXR

Maxar Technologies

$6.49

0.185 (2.93%)

17:12
08/19/19
08/19
17:12
08/19/19
17:12
Hot Stocks
Maxar Technologies' MDA awarded Canadian Space Agency contract »

MDA, a Maxar company, has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCI

Rogers Communications

$51.30

0.21 (0.41%)

17:06
08/19/19
08/19
17:06
08/19/19
17:06
Hot Stocks
Rogers 'disappointed' by CRTC decision on broadband wholesale rates »

Rogers Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.